Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dexlansoprazole for the treatment of esophagitis and GERD.

Drugs of today (Barcelona, Spain : 1998)·2010

Same author

Chronicles in drug discovery.

Drug news & perspectives·2007

Same author

The effect of inflammation on Fos expression in the ferret trigeminal nucleus.

European journal of oral sciences·2007

Same author

Spotlight on: clinical development of mycophenolate mofetil in multiple sclerosis.

Drug news & perspectives·2007

Same author

Rising to the pain challenge.

Drug news & perspectives·2007

Same author

Chronicles in drug discovery.

Drug news & perspectives·2006

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Ticagrelor.

Shelley L Davies¹

¹Institute of Science and the Environment, University of Worcester, Worcester, UK. s.davies@worc.ac.uk

Drugs of Today (Barcelona, Spain : 1998)

|May 27, 2010

Summary

This summary is machine-generated.

Ticagrelor, a novel P2Y12 receptor antagonist, offers rapid and sustained antiplatelet effects for coronary artery disease (CAD). Clinical trials show ticagrelor significantly reduces mortality from cardiovascular events, myocardial infarction, and stroke with a favorable safety profile.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: Jun 12, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Area of Science:

Cardiology
Pharmacology
Thrombosis

Background:

Coronary artery disease (CAD) is a leading cause of death in the U.S.
Current therapies like clopidogrel face challenges including patient resistance and slow action.
Novel antiplatelet agents are needed to improve outcomes in CAD patients.

Purpose of the Study:

To evaluate ticagrelor, a novel oral P2Y12 antagonist, for its antiplatelet efficacy and safety.
To assess the clinical benefits of ticagrelor in reducing major adverse cardiac events.
To compare ticagrelor's profile with existing antiplatelet therapies.

Main Methods:

In vitro and in vivo studies assessing antiplatelet effects.
Clinical investigations including DISPERSE, DISPERSE2, PLATO, ONSET/OFFSET, and RESPOND trials.
Evaluation of ticagrelor's impact on mortality, myocardial infarction, and stroke rates.

Main Results:

Ticagrelor demonstrated rapid, enhanced, and sustained antiplatelet activity.
Clinical trials indicated a significant reduction in mortality rates related to cardiovascular events.
Ticagrelor showed a favorable safety profile in patient populations studied.

Conclusions:

Ticagrelor represents a promising therapeutic option for patients with acute coronary syndrome.
The drug's efficacy in reducing major adverse cardiac events warrants its consideration in CAD management.
Ticagrelor's favorable profile supports its potential as a superior alternative to existing P2Y12 antagonists.